Board summary
Key figures
30,294
Registered population
58.2% aged 18–64
21.8%
Aged 65+
ICB 18.8% · England 17.9%
14.2%
Ethnic minority (non-White)
8.6% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
4,209
Hypertension register
+6.54% in 3 yrs · England +5.60%
209
SMI register
20.8% of Woking's
372
COPD register
Reviews +3.99% in 3 yrs
Forecast to 2030
5,026
Hypertension patients, 2030
+817 on today
57.2%
QRISK ≥20% on statins, 2030
+1.89pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy trails national and local benchmarks.
Lipid therapy for QRISK >= 20% is 10.3 percentage points below England's 63.6% (Woking 61.7%) and 64.2% in CKD, which may reflect recall gaps.
COPD register fell while national prevalence rose.
COPD prevalence fell over 2023 to 2025 (England +2.6%) to 1.2% (England 1.9%), an unadjusted benchmark range up to 202 patients that could reflect.
Hypertension control and annual reviews exceed benchmarks.
Hypertension treatment to target exceeds England's 70.3% (ICB 71.4%), alongside 84.4% COPD reviews (England 76.4%) and 88.8% SMI blood pressure checks (England 83.4%).
Population, age and ethnicity
Patients aged 65 and over reach 21.8%, exceeding borough and national levels
WB PCN covers 30,294 registered patients across three practices. Patients aged 65 and over account for 21.8% (6,616 patients), higher than Woking (15.3%), NHS Surrey Heartlands Integrated Care Board (18.8%) and England (17.9%). Those aged 18-64 make up 58.2% (Woking 63.4%, ICB 60.8%, England 62.7%), and children aged 0-17 represent 20.0% (Woking 21.3%, ICB 20.4%, England 19.6%). Based on Census usual residents rather than registered patients, White groups comprise 85.8% (Woking 78.4%, ICB 85.3%, England 81.1%) and Asian groups 8.6% (Woking 14.2%, ICB 7.7%, England 9.6%).
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Woking local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Woking LA) | 1,854 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Woking LA) | 796 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Woking LA) | 11.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.4 with 0.0% of registered patients in Core20
WB PCN records an average IMD decile of 8.4, less deprived than Woking (7.8), NHS Surrey Heartlands Integrated Care Board (7.9), and England (5.5). Average IMD is 8.6 at Madeira Medical, 8.2 at Parishes Bridge Med.pract, and 8.2 at Wey Family Practice. Registered patients in Core20 stand at 0.0% across all three practices (Woking 1.5%, ICB 0.8%, England 21.0%), and estimated Core20 residents total 0. Zero Core20 concentration suggests health equity reviews could focus on inclusion health and individual vulnerability rather than area deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
209
SMI register
0.67% recorded prevalence
117
Learning disability register
0.38% recorded prevalence
14
Care homes, 525 beds
In the PCN catchment
8.3%
Provide unpaid care
Woking, Census 2021
The PCN records 209 patients on the severe mental illness register (0.7% vs Woking 0.8%, NHS Surrey Heartlands Integrated Care Board 0.8%, England 1.0%) and 117 on the learning disability register (0.4% vs Woking 0.5%, ICB 0.5%, England 0.6%), alongside 14 catchment care homes with 525 beds. Lower crude recorded prevalence does not establish under-detection; clinical audits could examine whether differences reflect coding practice or true prevalence.
Severe mental illness: physical health checks
Severe mental illness prevalence is 0.7% (209 patients). Recorded checks exceed England: blood pressure reached 88.8% (England 83.4%), BMI reached 90.9% (England 82.1%), and alcohol status recording in psychosis reached 89.3% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,209
Hypertension register
+6.54%
Register growth, 3 yrs
Woking +6.51% · England +5.60%
+1.64pp
BP control, under 80
≤140/90 · +1.64pp aged 80+
+817
More patients by 2030
Forecast 5,026 (15.38%)
Hypertension case-finding and control
Hypertension prevalence is 13.6% (4,209 patients), against 13.2% in Woking, 14.3% in NHS Surrey Heartlands Integrated Care Board, and 15.2% in England. Recent blood pressure checks reach 92.6% (England 90.0%) and treatment to target is 75.3% (England 70.3%), including 72.6% under 80 and 84.3% aged 80+. Over 2023 to 2025, treatment to target grew +0.8% (England +3.6%). Among patients aged 80+, blood pressure control is 78.2% at Wey Family Practice and 90.0% at Madeira Medical. Lower recorded prevalence than England does not establish undiagnosed disease, but practice-level variation among older patients could be audited locally.
Lipids and statins
Lipid-lowering therapy reaches 53.2% for QRISK ≥ 20% patients (Woking 61.7%, NHS Surrey Heartlands Integrated Care Board 59.4%, England 63.6%) and 64.2% for CKD patients (England 70.3%). Lower therapy rates across high-risk groups may reflect differences in recall protocols, which practice audits could review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 34,489 | £2.70 | £2.24 | £1.86 | £93,120 |
| Cardiovascular (all), 2025 | 49,607 | £4.91 | £4.74 | £3.33 | £243,570 |
For lipid-regulating drugs 2026, cost per item is £2.70 across 34,489 prescribed items, compared to £2.50 in Woking, £2.24 in NHS Surrey Heartlands Integrated Care Board, and £1.86 in England. This equates to £28,971 more than at England's unit cost. Higher unit cost than comparators may reflect prescribing mix, which a review of local formulary choices could explore.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+11.80%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+5.13%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.2% (372 patients), matching Woking (1.2%) and below England (1.9%), with a 3-year change of -3.1% over 2023 to 2025 (England +2.6%). Annual COPD reviews reach 84.4% (England 76.4%). Asthma prevalence is 5.1% (1,501 patients; England 6.6%), while annual reviews reach 70.9% (England 65.7%), leaving an estimated gap of about 440 unreviewed patients. Asthma management items for ages 5–19 rate at 787 per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer register prevalence is 4.6% (1,434 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 completion at 24 months was 100.0% and MMR dose 1 was 96.7%, both meeting the 95.0% target. At age 5, MMR dose 1 is 94.3%, MMR dose 2 is 88.6% (5.7 pp below dose 1), and 4-in-1 booster coverage is 87.1%. Lower age-5 coverage could reflect recall timing, which a preschool vaccination audit would evaluate.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
Across NHS Surrey Heartlands ICB in 2022, 61.4% of cancers with a known stage (2,955 of 4,810) were diagnosed at stage 1 or 2, exceeding England's 55.3% but sitting 13.6 pp below the 75.0% national ambition by 2028, requiring about 650 extra early-stage diagnoses across the ICB. Known-stage coverage was 67.7% (4,810 of 7,106 cancers; England 67.0%). Early staging reached 88.2% in breast but 48.1% in bowel. Within WB PCN, cervical screening reached 71.4% (England 66.8%), falling 2.3% over 2023 to 2025 (England -1.0%), with Parishes Bridge Med.pract at 67.5%. While ICB early staging exceeds the national rate, trailing screening trends could delay diagnosis without proactive recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For July 2026 (provisional), Ashford and St Peter's Hospitals NHS Foundation Trust met the 28-day faster diagnosis standard at 85.5% (above the 75.0% standard; England 79.3%; Royal Surrey NHS Foundation Trust 82.6%; Frimley Health NHS Foundation Trust 87.9%). However, 62-day referral to treatment was 76.4%, below the 85.0% standard by 8.6 pp (England 71.2%; NHS Surrey and Sussex Integrated Care Board 71.5%; Royal Surrey NHS Foundation Trust 84.5%). Across all diagnostic tests, 23.1% waited 6+ weeks (England 23.1%; Frimley Health NHS Foundation Trust 7.5%), with colonoscopy reaching 49.6% and gastroscopy 56.7%. Provider diagnostic delays could reflect endoscopy backlogs before treatment.
| Pathways within standard (%) | Ashford and St Peter's | Royal Surrey | Frimley Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 85.53 | 82.62 | 87.95 | 79.29 | 79.32 |
| 31-day treatment (96%) | 94.21 | 96.43 | 92.89 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 76.38 | 84.48 | 81.84 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Ashford and St Peter's | Royal Surrey | Frimley Health | England |
|---|---|---|---|---|
| MRI | 0.09 | 0.00 | 12.85 | 21.40 |
| CT | 9.27 | 0.15 | 0.63 | 9.92 |
| Echocardiography | 0.97 | 1.55 | 3.35 | 28.48 |
| Colonoscopy | 49.61 | 0.00 | 22.84 | 30.83 |
| Gastroscopy | 56.74 | 0.00 | 7.43 | 29.02 |
| All 15 DM01 tests | 23.12 | 8.82 | 7.49 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026 (provisional), Surrey residents accounted for 109,530 community care contacts and 66,060 community care activities, while NHS Surrey and Sussex Integrated Care Board recorded 309,615 contacts. Adults aged 65+ made up 69.6% of contacts with residents (76,215 of 109,530). These figures represent experimental submitting-provider activity rather than PCN patient volume. Community service use could reflect high older adult care needs across the borough.
Practice variation and patient experience
Practice phone access varies by 31.5 percentage points alongside wide overall satisfaction spreads
In 2025/26, overall QOF achievement spanned 92.2% at Parishes Bridge Med.pract to 98.8% at Madeira Medical (England 92.5%). Vaccination achievement ranged 16.9 percentage points, from 74.2% at Wey Family Practice to 91.1% at Parishes Bridge Med.pract. Personalised care adjustments were 5.0% at Madeira Medical, and 9.2% at both Parishes Bridge Med.pract and Wey Family Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Wey | 102 | 0.0 | 62.6% | 68.1% | 88.4% |
| Madeira Medical | 97 | 0.0 | 65.4% | 79.7% | 79.8% |
| Parishes Bridge | 83 | 0.0 | 33.9% | 79.2% | 59.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 measures trail England's three-year change, led by COPD prevalence
Across 25 compared indicators, 11 trail England's three-year change. Trailing measures are led by COPD prevalence (-3.1% versus England's +2.6%), breast screening (+4.8% versus +8.4%), hypertension treated to target (+0.8% versus +3.6%), and QRISK ≥ 20% lipid therapy (+3.7% versus +6.2%). Conversely, heart failure reviews grew +34.0% to 82.7% (England +8.7% to 78.5%) and asthma reviews grew +11.8% to 70.9% (England +4.4% to 65.7%). This pattern may reflect structured review recall outpacing preventive treatment follow-up, which clinical record audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Breast screening (53-70)
Hypertension treated to target
QRISK statin treatment
Stroke register
Heart failure reviews
Asthma reviews
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Woking | Asset | PCN | Woking |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (525 beds) | n/a | Schools (catchment) | 25 | n/a |
| Children's centres | 2 | 8 | Places of worship | 12 | 49 |
| Libraries | 3 | 1 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 2 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 1 | 2 | Primary academies | 4 | 19 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
High-risk cardiovascular lipid therapy review
Lipid therapy for QRISK >= 20% is 53.2%, below England (63.6%) by 10.3 pp and Woking (61.7%) by 8.5 pp, while CKD lipid therapy is 64.2% (England 70.3%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
COPD register case-finding and audit
COPD prevalence is 1.2% (372 patients) against 1.9% in England and 1.2% in Woking, giving an unadjusted benchmark range of -16 to +202 patients. For discussion, practices could search records for smokers or patients with repeated respiratory prescribing lacking a COPD code and raise spirometry access with system partners. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Learning disability register coding validation
Learning disability register prevalence is 0.4% (117 patients) versus 0.5% in Woking and 0.6% in England, giving an unadjusted range of +32 to +61 patients. For discussion, practices could audit clinical records for historic learning disability codes and cross-check lists where social-care data sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Severe mental illness register review (p4) | Severe mental illness: QOF prevalence | MHIS · From Harm to Hope | PCN |
| Older cohort hypertension review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | Practice |
| Preschool immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake and recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · High-risk cardiovascular lipid therapy review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Hypertension register | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · COPD register case-finding and audit (p12) | COPD register · COPD: QOF prevalence | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Learning disability register coding validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
